Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida

American Journal of Epidemiology

Volumn 148, Issue 1, 1998, Pages 30-37

  Shaw, Gary M ^a   Rozen, Rima ^b   Finnell, Richard H ^c   Wasserman, Cathy R ^d   Lammer, Edward J ^e  

^a California Birth Defects Monitoring Program   (United States)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c TEXAS A AND M UNIVERSITY   (United States)

^d WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Abnormalities; Folic acid; Genotype; Neural tube defects; Spinal dysraphism; Vitamins

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA; FOLIC ACID;

ANENCEPHALUS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; SPINA BIFIDA; VITAMIN INTAKE;

EID: 0032125774     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009555     Document Type: Article

References (31)

1. Medical Research Council Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-7.
2. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5.
3. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural tube defects. Lancet 1995;345:149-51.
4. Nosel PG, Klein NW. Methionine decreases the embryotoxicity of sodium valproate in the rat: in vivo and in vitro observations. Teratology 1992;46:499-507.
5. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. (Letter). Nat Genet 1995;10:111-13.
6. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
7. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-16.
8. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997;17:569-73.
9. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. QJM 1995;88:763-6.
10. van der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1.
11. van der Put NM, van den Heuvel LP, Steegers-Theunissen RP, et al. Decreased methylene tetrahydrofolate reductase activity due to the 677C→T mutation in families with spina bifida offspring. J Mol Med 1996;74:691-4.
12. Ou CY, Stevenson RE, Brown VK, et al. 5,10-Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996;63:610-14.
13. Kirke PN, Mills JL, Whitehead AS, et al. Methylenetetrahydrofolate reductase mutation and neural tube defects. (Letter). Lancet 1996;348:1037-8.
14. Papapetrou C, Lynch SA, Burn J, et al. Methylenetetrahydro folate reductase and neural tube defects. (Letter). Lancet 1996;348:58.
15. Posey DL, Khoury MJ, Mulinare J, et al. Is mutated MTHFR a risk factor for neural tube defects? (Letter). Lancet 1996;347:686-7.
16. Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6:219-26.
17. Wasserman CR, Shaw GM, O'Malley CD, et al. Parental cigarette smoking and risk for congenital anomalies of the heart, neural tube, or limb. Teratology 1996;53:261-7.
18. Croen LA, Shaw GM, Jensvold NG, et al. Birth defects monitoring in California: a resource for epidemiological research. Paediatr Perinat Epidemiol 1991;5:423-7.
19. Block G, Hartman AM, Dresser CM, et al. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69.
20. Schwartz EI, Khalchitsky SE, Eisensmith RC, et al. Polymerase chain reaction amplification from dried blood spots on Guthrie cards. (Letter). Lancet 1990;336:639-40.
21. Selvin S. Statistical analysis of epidemiologic data. 1st ed. New York, NY: Oxford University Press, 1991. (Monographs in epidemiology and biostatistics, vol 17).
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
23. Steegers-Theunissen RP, Boers GH, Trijbels FJ, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994;43:1475-80.
24. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4.
25. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
26. Wilcken DE, Wang XL. Relevance to spina bifida of mutated methylenetetrahydrofolate reductase. (Letter). Lancet 1996;347:340.
27. de Franchis R, Sebastio G, Mandato C, et al. Spina bifida, 677T→C mutation, and role of folate. (Letter). Lancet 1995;346:1703.
28. Scriver CR, Kaufman S, Eisensmith RC, et al. The hyperphenylalanemias. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease. 7th ed. New York, NY: McGraw-Hill Book Company, 1995:1015-75.
29. Shaw GM, Lammer EJ, Wasserman CR, et al. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 1995;346:393-6.
30. Shaw GM, O'Malley CD, Wasserman CR, et al. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995;59:536-45.
31. Li DK, Daling JR, Mueller BA, et al. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies. Epidemiology 1995;6:212-18.